BIOARTIFICIAL ORGANS III--TISSUE/IMMUNOISOLATION/TRIALS

描述(取自应用程序) 生物人工器官III：组织来源、免疫隔离和 临床试验“计划于2000年10月7日至11日(将在达沃斯举行， 瑞士)，探索当代和新兴的生物人工方法 器官，因为它们与不同的领域接口。生物医学应用和 临床试验将是重点。其目的是充分利用 跨学科方法：化学、物理化学、材料科学、 聚合物化学、细胞培养、重组DNA技术、生物过程 工程学和临床科学。具体地说，它将把三个 通常不会在单一会议上互动的专业人士团体： (1)材料和聚合物科学家，(2)生物工艺工程师，(3)医学 专业人士。重点将放在这些学科的横截面上。 主要覆盖范围包括胰腺、肝脏、肾脏、皮肤、牙齿和骨骼。 区域。该计划将强调科学基础，演变为 并回顾每个领域的临床状况。一次尝试将是 制造成在聚合物中具有大约2SM5/50%的分裂， 工程学和生物医学类别。此外，主办方 预计参与者将来自学术界、工业界和临床 各机构在大致相同的基础上。强者的表象 美国的偶然性对于继续多学科至关重要，这是 生物人造器官系列培育了。这种情况在2000年尤为严重，因为 许多美国大学、医疗中心和公司正在与全球 将生物人造器官从研究转移到临床的合作伙伴或赞助商 和市场作为评估新设备所需的参数和指标 治疗方法也在研发中。监管者、高管的参与 来自大中小型企业的研究总监和 包括会议前的生物技术投资者峰会是对 程序。会议将有戈登会议的风格。美联队 工程基金会(纽约)将承担以下主要责任 行政、后勤、机械、宣传、住房和金融 会议。资金支持是从NIH，NSF，Whitaker Fdn， 青少年糖尿病基金会、FNS(瑞士)、欧洲联盟和其他 消息来源。会议记录将以同行评议的形式公布。 卷(纽约科学院)。

DESCRIPTION (taken from the application) A conference, "Bioartificial Organs III: Tissue Sourcing, Immunoisolation and Clinical Trials," is proposed for October 7-11, 2000 (to be held in Davos, Switzerland), to explore contemporary and emerging approaches of bioartificial organs as they interface with different fields. Biomedical applications and clinical trials will be highlighted. The intent is to make use of a fully interdisciplinary approach: chemistry, physical chemistry, materials science, polymer chemistry, cell culture, recombinant DNA technology, bioprocess engineering, and clinical sciences. Specifically, it will bring together three groups of professionals, who do not normally interact at a single conference: (1) materials and polymer scientists, (2) bioprocess engineers, and (3) medical professionals. The emphasis will be at the cross-section of these disciplines. The main coverage will be in the pancreas, liver, kidney, skin, dental and bone areas. The program will stress scientific fundamentals, evolve into applications and review the clinical status in each area. An attempt will be made to have approximately 2SM5/50 percentage split amongst the polymer, engineering and biological-medical categories. In addition, the organizers expect that the participants will come from academia, industry and clinical institutions on approximately even basis. The representation of a strong American contingency is critical to continue the multidisciplinary, which the bioartifical organ series has fostered. This is particularly acute In 2000 as a number of US universities, medical centers and firms am integrating with global partners or sponsors to move bioartificial organs from research to the clinic and marketplace as the parameters and metrics needed to evaluate new devices and therapies are being developed. The participation of regulators, executives and research directors from large small and medium sized enterprises and the inclusion of a pre-conference biotechnology investors summit complements the program. The conference will have a Gordon Conference style. The United Engineering Foundation (New York) will assume primary responsibilities for administration, logistics, mechanics, publicity, housing, and finance for the conference. The funding support is requested from NIH, NSF, Whitaker Fdn., Juvenile Diabetes Fdn., FNS (Switzerland), European Union and from other sources. The proceedings of the conference will be published as a peer reviewed volume (The New York Academy of Sciences).